Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 21,310 |
|
|||||
| News | - | ||||||
| Day High | 0.0394 | Low High |
|||||
| Day Low | 0.0376 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncotelic Therapeutics Inc (QB) | OTLC | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00108 | 2.82% | 0.0394 | 13:37:32 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0376 | 0.0376 | 0.0394 | 0.0394 | 0.03832 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8 | 21,310 | US$ 0.037921 | US$ 808 | - | 0.01 - 0.05 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:37:32 | 2,000 | US$ 0.0394 | USD |
Oncotelic Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.97M | 395.84M | 174.23M | 70k | -7.9M | -0.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncotelic Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/02/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/30/2023 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/23/2023 | 09:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/18/2023 | 16:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/13/2023 | 08:25 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 7/13/2023 | 08:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/30/2023 | 08:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.04 | 0.044 | 0.0361 | 0.040447 | 25,436 | -0.0006 | -1.50% |
| 1 Month | 0.0375 | 0.044 | 0.036 | 0.0411447 | 68,786 | 0.0019 | 5.07% |
| 3 Months | 0.04 | 0.045 | 0.0301 | 0.0396249 | 78,295 | -0.0006 | -1.50% |
| 6 Months | 0.031 | 0.045 | 0.0233 | 0.0377005 | 79,605 | 0.0084 | 27.10% |
| 1 Year | 0.04655 | 0.05 | 0.01 | 0.0307669 | 158,489 | -0.00715 | -15.36% |
| 3 Years | 0.30 | 0.34 | 0.01 | 0.1054192 | 180,931 | -0.2606 | -86.87% |
| 5 Years | 0.24 | 0.36 | 0.01 | 0.1110704 | 181,090 | -0.2006 | -83.58% |
Oncotelic Therapeutics (QB) Description
| Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas). |
